Drove preclinical discovery/development projects at the bench and by managing a direct report, orchestrating cross-functional teams, and partnering with CROs. Concurrently lead small-molecule inhibitor/degrader programs, created novel functional genomics screens, and enhanced gene-editing applications for target validation.

Bridged the gaps between biochemistry, molecular biology, mouse models and human genetics to uncover therapeutic opportunities for crippling pancreatic diseases. Identified the IRE1α and PERK branches of the Unfolded Protein Response (UPR) as potent anti-cancer targets in xenograft and spontaneous genetic models of pancreatic neuroendocrine tumors (PanNETs). Detailed the paradigm-shifting mechanism by which a p.R90C mutation in elastase 3B drives familial pancreatitis

Elucidated the in vivo mechanism of retro-translocation of cholera toxin from the endoplasmic reticulum (ER) to the cytoplasm in order to detail protein folding and degradation pathways